









Markets
/
Stocks
/
nasdaq-vtrs
/

Viatris Inc

VTRS

10.490USD

-0.040-0.38%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

12.23BMarket Cap

LossP/E TTM



Viatris Inc

10.490

-0.040-0.38%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Viatris Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Viatris Inc's Score

Industry at a Glance

Industry Ranking

40 / 159

Overall Ranking

106 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Hold

Current Rating

11.744

Target Price

+11.53%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Viatris Inc Highlights

StrengthsRisks

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s ARV franchise. The Company’s portfolio comprises approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands and generics, including complex products. The Company operates manufacturing sites across worldwide that produce oral solid doses, injectables and complex dosage forms.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Fairly Valued

The company’s latest PE is -3.58, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 985.43M shares, decreasing 4.65% quarter-over-quarter.

Held by Chris Davis

Star Investor Chris Davis holds 66.38M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 7.07, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 3.58B, representing a year-over-year decrease of 5.65%, while its net profit experienced a year-over-year decrease of 98.59%.

Score

Industry at a Glance

Previous score

7.07

Change



Financials

5.75

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

2.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.87

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

8.07

Key Metrics

Free cash flow

No Data

Viatris Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 8.93, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -3.58, which is -8391.14% below the recent high of 296.91 and -7198.55% above the recent low of -261.36.

Score

Industry at a Glance

Previous score

8.93

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 40/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 6.40, which is lower than the Pharmaceuticals industry's average of 7.77. The average price target for Viatris Inc is 12.00, with a high of 15.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

6.40

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Hold

Current Rating

11.744

Target Price

+11.53%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Viatris Inc

VTRS

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 8.96, which is higher than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 10.83 and the support level at 9.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.91

Change

0.05

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.043

Buy

RSI(14)

61.938

Neutral

STOCH(KDJ)(9,3,3)

72.916

Neutral

ATR(14)

0.204

Low Volatility

CCI(14)

130.731

Buy

Williams %R

19.449

Overbought

TRIX(12,20)

0.192

Sell

StochRSI(14)

75.788

Neutral

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

10.402

Buy

MA10

10.379

Buy

MA20

10.212

Buy

MA50

10.122

Buy

MA100

9.759

Buy

MA200

9.511

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 85.20%, representing a quarter-over-quarter increase of 1.46%. The largest institutional shareholder is The Vanguard, holding a total of 144.70M shares, representing 12.51% of shares outstanding, with 5.54% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

144.70M

+0.48%

T. Rowe Price Associates, Inc.

Star Investors

76.96M

+5.89%

Davis Selected Advisers, L.P.

Star Investors

66.38M

+2.20%

BlackRock Institutional Trust Company, N.A.

61.38M

-4.57%

State Street Investment Management (US)

55.29M

-10.04%

Dimensional Fund Advisors, L.P.

31.26M

+47.05%

Geode Capital Management, L.L.C.

31.23M

+0.17%

Invesco Capital Management LLC

Star Investors

24.15M

+4.00%

Deerfield Management Company, L.P.

24.02M

+0.13%

Columbia Threadneedle Investments (US)

22.77M

+5.38%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 8.42, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.84. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.